FDA Approves Crizanlizumab: Here Is A New Drug For Sickle Cell Disease

It isn’t the easiest drug name to pronounce, but crizanlizumab-tmca will be the first ever available targeted therapy for sickle cell disease. On Friday, the U.S. Food and Drug Administration (FDA) announced that they have given Novartis the go-ahead to begin marketing Adakveo, the somewhat easier to say brand name for crizanlizumab-tmca.